Aimmune Therapeutics, Inc. (AIMT) Earns Buy Rating from Analysts at Roth Capital
Roth Capital started coverage on shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) in a research report sent to investors on Monday, MarketBeat reports. The firm issued a buy rating and a $60.00 price objective on the biotechnology company’s stock.
Several other brokerages also recently issued reports on AIMT. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a hold rating to a buy rating and set a $34.00 target price for the company in a research note on Wednesday, November 8th. Credit Suisse Group increased their price target on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an outperform rating in a report on Monday, October 23rd. Wedbush reissued an outperform rating and issued a $70.00 price target (up from $42.00) on shares of Aimmune Therapeutics in a report on Monday, October 23rd. Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the company a buy rating in a report on Saturday, October 21st. Finally, BidaskClub cut shares of Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Aimmune Therapeutics currently has an average rating of Buy and a consensus price target of $49.40.
Shares of Aimmune Therapeutics (NASDAQ AIMT) opened at $35.74 on Monday. Aimmune Therapeutics has a one year low of $15.97 and a one year high of $37.50.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. equities analysts forecast that Aimmune Therapeutics will post -2.57 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Aimmune Therapeutics, Inc. (AIMT) Earns Buy Rating from Analysts at Roth Capital” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/aimmune-therapeutics-inc-aimt-earns-buy-rating-from-analysts-at-roth-capital/1723051.html.
In other Aimmune Therapeutics news, CEO Stephen George Dilly sold 100,000 shares of the stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $25.01, for a total value of $2,501,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Douglas T. Sheehy sold 1,905 shares of the stock in a transaction dated Thursday, November 9th. The shares were sold at an average price of $33.00, for a total transaction of $62,865.00. Following the completion of the transaction, the insider now directly owns 1,905 shares in the company, valued at $62,865. The disclosure for this sale can be found here. Over the last three months, insiders sold 317,720 shares of company stock worth $8,400,244. Insiders own 24.56% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its holdings in Aimmune Therapeutics by 10.1% in the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 499 shares during the period. Teachers Advisors LLC raised its holdings in Aimmune Therapeutics by 2.6% in the 1st quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock valued at $964,000 after acquiring an additional 1,120 shares during the period. Legal & General Group Plc raised its holdings in Aimmune Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after acquiring an additional 1,634 shares during the period. American International Group Inc. increased its holdings in shares of Aimmune Therapeutics by 8.1% during the third quarter. American International Group Inc. now owns 23,591 shares of the biotechnology company’s stock worth $585,000 after purchasing an additional 1,764 shares during the period. Finally, Strs Ohio increased its holdings in shares of Aimmune Therapeutics by 6.1% during the second quarter. Strs Ohio now owns 34,600 shares of the biotechnology company’s stock worth $711,000 after purchasing an additional 2,000 shares during the period. 73.37% of the stock is currently owned by hedge funds and other institutional investors.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.